CD19 and precursor B-cell acute lymphoblastic leukemia: In a recent clinical trial (NCT02374333), Myers et al., evaluated the antitumor response, persistence, and toxicity of CD19-redirected CAR-T cells with humanized scFvs as the targeting domain in children and young adults with B-ALL (72 patients) and B-lymphoblastic lymphoma (2 patients) (Table 1) [31].